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their morph and/or cell life stages, antimicrobial or antimycotic resistance profiling,
epidemiological dispersion. Herein, we aim at reviewing the current state-of-the-art on
proteomic protocols designed and set-up for translational and diagnostic microbiological
purposes, from axenic pathogens' characterization tomicrobiota ecosystems' full description.
The final goal is to describe applications of the most common MALDI-TOF MS platforms to
advanced diagnostic issues related to emerging infections, increasing of fastidious bacteria,
and generation of patient-tailored phylotypes.
This article is part of a Special Issue entitled: Trends in Microbial Proteomics.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.Keywords:
Clinical microbiology
Emerging pathogens
Translational proteomics
MALDI-TOF MSed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative
cial use, distribution, and reproduction in any medium, provided the original author and
itled: Trends in Microbial Proteomics.
ology and Metagenomics Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4,
6; fax: +39 06/68592218.
m, lorenza.putignani@opbg.com (L. Putignani).
uthors. Published by Elsevier B.V. All rights reserved.
70 J O U R N A L O F P R O T E O M I C S 9 7 ( 2 0 1 4 ) 6 9 – 8 7Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
2. MALDI-TOF MS-based ID in clinical microbiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
3. MALDI-TOF MS-based microbial typing and antibiotic resistance profiling . . . . . . . . . . . . . . . . . . . . . . . . 75
4. MALDI-TOF MS-based ID and typing of yeasts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
5. Mono and polymicrobial communities: the case of blood cultures . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
5.1. The pre-analytical step: the usage of homebrew methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.2. The pre-analytical step: the usage of the Sepsityper™ kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.3. The post-analytical step: the ID processing algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6. Proteomics and metaproteomics of microbial ecosystems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
7. Outlook on other MALDI-TOF MS applications and future developments . . . . . . . . . . . . . . . . . . . . . . . . 82
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831. Introduction
In the last few years, proteomics has dealt with emerging or
re-emerging pathogens, including neglected agents, in order
to provide support in taxonomic microbial classification,
invasion mechanisms, life cycle stage switching, antigen
variation, drug target and drug resistance discovery, and
infection epidemiology.
Genomic data are currently growing at an extraordinary
rate. However, this huge amount of descriptive work has only
scraped the surface of the microbial biodiversity, endowed
with environmental, opportunistic and pathogenic strain
patterns, still lacking comprehensive functional insights into
the microbe-host cross-talk. The highly microbial diversity
indicates strategies devised to potentiate specialized adaptation
mechanisms within host or ecological niches, through genetic
material transfers [1], post-transcriptional machineries [2],
proteome modulation and controlling in response to
specific external stimuli [3]. While genomics may provide a
comprehensive snapshot on everything related to nucleic
acids, proteomics ensures the actual description of specific
proteins or complexes of proteins in their biological milieu.
Furthermore, proteomes are much more multiform and
dynamic than related up-stream genomes, hence requiring
complex experimental pipelines, including separation, detection,
and data processing, to highlight either protein content and/or
modifications during the complex host–parasite interaction
phase (e.g., infection, propagation stages) (Fig. 1).
The successful coupling of multidimensional separations
with mass spectrometry (MS) for protein and peptide
analyses has been achieved with the advent of the ionization
Matrix-assisted laser desorption ionization (MALDI) and
Electrospray ionization (ESI) techniques, assisted by the
evolvement of new powerful MS instrumentations. While
MALDI is usually combined with gel-based separations, ESI
is frequently coupled with “on-line” (High-pressure liquid
chromatography) HPLC or reversed-phased (RP) LC separations
[4,5].
Two main analytical approaches are commonly used for
protein analyses for proteome separation and characterization:
“top-down” and “bottom-up”. The top-down is an emerging
design for the analysis of intact proteins separated by HPLC andidentified by MS [6]. In the bottom-up approach, samples
require a gel-based purification step, followed by an enzymatic
or chemical digestion that provides peptides separated by
multidimensional chromatography, such as 2-D-HPLC, and
finally identified by tandem MS [7,8]. Otherwise, the crude
protein extract may be digested directly, followed by on-line LC
or off-line mode coupled-tandemMS (i.e., shotgun proteomics).
Top-down approaches allow an extensive protein identification
(ID), including amino acid sequence characterization and
post-translational modifications since they are based on the
intact molecules of interest [9].
Peptide and intact protein analysis can be conducted using
either the time of flight (TOF) MS, or the Fourier transform ion
cyclotron resonance (FT-ICR), that ensures a performance in a
wide mass range and, in the case of FT-ICR, a high mass
accuracy. Other types of instruments (e.g., hybrid linear ion
trap [LTQ]-orbitraps, LTQ-FTICRs, or quadrupole ion trap) can
also be applied to identify proteins [10]. From a general point
of view, MALDI-TOF MS is ideal for relatively clean and less
complex samples, with the targeted protein resulting
dominant in the starting sample. Infusion ESI–MS/MS should
be used when the sample is clean and at low complexity, with
the scope of characterizing all multiple analytes and possible
modifications on them. The complexity item can be managed
in terms of appropriate proteomic technological platforms by
including in translational and diagnostic microbiology a
miscellaneous of methodological pipelines to analyze global
proteomes or part of them. This will therefore reflect
microorganism status and complexity to respond to specific
needs: i) proteomic phenotyping supported by MALDI-TOF MS
peptide fingerprinting; ii) proteome charting by bottom-up
shotgun profiling; iii) sub-proteome relative and absolute
quantitation by differential labelling and targeted analysis,
respectively; and iv) community based analysis of operational
taxonomic units (OTUs) frommicrobial communities (e.g., gut,
airway, salivary microbiota) by LC-ion trap MS/MS (Fig. 2).
Therefore, dealing with pathogens or opportunistic path-
ogens by proteomic approaches means to design and set-up
the proper technology for general microbiological or specific
diagnostic purposes [11,12]. Indeed, each diagnostic or trans-
lational task needs specific pre- and analytical solutions
and proper technological platforms. Therefore, a wide range
1. MICROBIAL  AXENIC CULTURES
2. MONOMICROBIC AND POLYMICROBIAL 
CULTURES: direct sample
( e.g. blood cultures, liquor, BAL, urine)
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Fig. 1 – Main proteomic approaches driving discovery and characterization of peptides and proteins of translational and clinical
interest inmicrobiology. The different objectives require specific approaches to solve the diverse translational and diagnostic needs.
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comprehensive description of protein patterns and protein
markers, through whole proteome mining of microbial
pathogens [13]. Against pursuing with the characterization
of axenic microbes, which represents a shortcut in pathogen
characterization,major challenges still rely on the optimization
of ID procedures for fastidious, slow growing and anaerobe
bacteria and in the generation of microbial charts describing
the complexity of polymicrobial cultures from direct samples
(e.g., blood cultures, liquor, urine, bronchoalveolar lavage [BAL])
or microbial ecosystems (Fig. 3). However, the pathogen is now
considered in the complexity of its ecological niche within the
host (infection site) or in the context of its relationships with
environment and host. For these reasons, the systems biology
may represent the choice of election in the study of microbial
pathogens integrated in their ecological “context” (e.g., “gut
microbiota”) [14]. MS and MS/MS proteomic approaches are
determinant for all pathogens characterized by complexity of
stage or morph (type) (e.g., filamentous fungi) and multiple
components of the life cycle (e.g., oral–faecal parasites, such as
Cryptosporidium spp., a metabolic evolutionary model for manyPeak semi-quantification 
by iTRAQ-LC-MS/MS 
Peptide fingerprinting by 
MALDI-TOF MS •Proteomic phenotyping 
Peak characterisation 
by LC MS/MS and gel-
based TOF-TOF MS-MS
Peak characterisation 
by LC -ITMS/MS
•Multicomponent analysis 
of communities
•Differentially labelled 
subproteome charting
•Proteome charting: shot-gun
•Targeted-protein searching
Fig. 2 – Proteomic technological platforms and related
applications to current translational and clinical
microbiology. The increasing complexity of the presently
employed proteomic approaches is related to a growing
technological complexity.parasites, fungal and anaerobe or modified aerobe bacteria).
Nowadays, one of themost revolutionary proteomic innovation
lies in the direct and robust top-down MALDI-TOF MS, which
represents a peerless tool for microbiological diagnostics,
becoming a reference method to identify bacteria, yeasts and
filamentous fungi at genus, species and strain level [15].3. BACTERIA COMMUNITIES:
fungal morphs, parasite life-cycles, 
gut, salivary, airway, lung microbiota
Fig. 3 – Main fields of proteomic applications to basic (axenic
cultures) and advanced (direct samples, bacterial
communities) microbiological pipelines.
72 J O U R N A L O F P R O T E O M I C S 9 7 ( 2 0 1 4 ) 6 9 – 8 7A standardized and simple protocol, based on single plate
colony picking and direct streaking onto MALDI polished
target plate, easy chemical treatment (e.g., peptide extraction
by formic acid, FA), and proton transfer by α-cyano-4-
hydroxycinnamic acid (CHCA), allows prompt and accurate
microorganism IDs, generating peptide-based spectra profiles
interpreted by original and customized databases (Fig. 4). The
generation of peptide profiling makes the top-down proteomics
as one of the most efficacious and advanced strategy in
diagnostic microbiology pipelines.2. MALDI-TOF MS-based ID in
clinical microbiology
Pathogen characterization, based on MALDI-TOF MS finger-
printing profiling, now represents an affordable and con-
solidated procedure in routine diagnostic microbiology
which is progressively covering the entire spectrum of the
four-step diagnostic pipeline paradigm: detection, ID,
susceptibility testing, epidemiology. Wide microorganism
profiling multiplicity, available as original reference data-
base (ORD, provided with the BioTyper and Vitek MS
softwares) [16], is currently guaranteeing fulfilment of in-
vestigation for the most important and common pathogens
(Fig. 4). If a clinically relevant pathogen is detected by
solid medium growth, it can be further tested for ID, drugPeptide profiling
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Fig. 4 – Patternmultiplicity of MALDI-TOFMS fingerprinting of mi
interpreted by matching them against reference spectra databas
providing bacterial identification.susceptibility, and epidemiological typing, independently
or after growth condition setting. The MALDI-TOF MS
protein fingerprint employs a pattern-matching algorithm
to compare microbial cell extracted peak lists with a reference
database, hence creating a consensus “biomarkers” peak list,
characterized by averaged m/z and intensity. However, only a
couple of works on biomarkers' selection has provided the first
proof of evidence for bacteria and fungi classifiers associated
with ID MS profiling [17,18]. The Bruker MALDI BioTyper is a
MALDI-TOF MS based bench-top platform for rapidly
identifying bacteria, yeasts and filamentous fungi. Its wisely
curated database includes quality-controlled entries of
more than 3900 strains from over 2000 well-characterized
microbial species (http://ir.bruker.com/phoenix.zhtml?c=
121496&p=irol-newsArticle&ID=1552077&highlight=) [19].
However, the dedicated design and compilation of customized
new reference databases (NRDs) is often crucial to “resolve”
and assess specific fingerprinting profiling not properly match-
ing against ORDs. Indeed, while MALDI-TOF MS misiden-
tification rate appears extraordinary low, as showed by a
plethora of works published so far [17,20–25], the bottleneck
of the ID pipeline still lies in the inadequacy of reference
libraries, lacking “adequate” matching patterns for “each type”
of bacterial species and/or strain. Database upgrades are
therefore essential elements to refine the MALDI-TOF MS
technique, allowing the method to increase its discriminatory
power.Peptide Fingerprinting
Pathogen identification
REFERENCE SPECTRA
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croorganisms species and types. The generated “profiles” are
es, hence assigning each of them to a specific pattern and
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spp. [27–29], Haemophilus influenzae [30], Helicobacter pylori [31],
Bartonella spp. [32], Mycobacterium spp. [33–36]; anaerobes
[37–41]; Gram-negative and Gram-positive bacteria of clinical
relevance [42–51] and aero-tolerants [52] offer the major
challenging competition amongst clinical microbiological
laboratories for advanced database compilation and easy
implementation of routine ID. However, the need to identify
bacteria at biotype and serotype levels (e.g., for Brucella spp.
and Shiga toxin-producing Escherichia coli, STEC) [53–58]
and the emerging interest in environmental- [29,59,60],
food-related [61–67] and bioterrorism-agent bacteria [68,69],
is definitely improving the MALDI-TOF MS-based routine
in clinical laboratories [26]. Microorganism ecology and
metabolism (e.g., environmental or clinical yeast isolates,
filamentous fungi or morphs, fastidious bacteria), have also
driven until now pre- and analytical process setting
for MALDI-TOF MS optimization, responding to specific
patient-tailored clinical issues (e.g., clinical categories such
as immunocompromised or chronic patients and major
related infections) [70–74], sample types (e.g., culture-based
or direct sample) [75,76], and infection spreading modality
(e.g., nosocomial bacterial or fungal strains) [18,77] (Fig. 3).
In the basic procedure, starting from a cultured colony, ID
is performed by matching the measured peptide mass
fingerprinting against the MALDI BioTyper ORD, which can
be followed by a final review performed by a trained
microbiologist. Therefore, in the basic workflow, ID can be
carried out within a few minutes including database
searching. Multiple colonies can be spotted on a single target,
and simultaneous 30–50 IDs can be approximately performed
every hour. At basic-level (i.e., microbial ID), the MALDI
BioTyper up to now seems to offer high specificity, almost
no false positive rates, little operational costs, low technical
barriers for operators, and considerably faster time-to-result
compared to classical morphotyping (e.g., microscopic and
macroscopic ID), phenotyping (e.g., biochemical assimila-
tion patterns) or advanced genotyping methods (e.g., rep-
PCR, sequencing). However, customized library compilation
may dramatically improve specific diagnostic pipelines,
such as multi-drug resistant (MDR) strain tracking, specific
pathogen lineages IDs (e.g., nosocomial circulating strains
from immunocompromised patients, children or neonates;
food-related strains). Nevertheless, the crucial drawback of
private/local databases lies in their limited availability to the
scientific community, which actually hampers the sharing of
accessible MS profiles for inter-laboratory consultation.
Recently, Böhme et al. in their paper [78], have thoroughly
described the web-based SPECLUST application (http://bioinfo.
thep.lu.se/speclust.html), able to compare peak mass lists, and
the Spectra-Bank database (www.spectrabank.org), a reference
repository for bothmicrobial ID and “typing”. Indeed, such tools
may provide phyloproteomic clustering topologies, similarly
to previous tracing methods for genotyping, extending the
concept of “gene ontologies” to phenotype (proteome) onto-
logies [79]. Stable phenotype profilings strongly correlate with
pre-analytical procedures. Indeed, engineering of reference
databases relies on unvarying growth conditions. Especially
for filamentous fungi, standardised growth conditions on
selected solid media, represent the key element to producetechnical reference and analytical profiling fromheterogeneous
life cycle stages, hence providing reproducible proteomic
profiling and related reference databases [18,80]. On the other
side, also bacterial proteins are affected by culture
conditions, with different proteins produced by vegetative
bacteria when they are cultured in different growth media
[81]. It seems that a core set of small proteins remains
constant under different culture media conditions, in-
cluding minimal medium (i.e., M9), rich media (i.e., tryptic
soy or Luria-Bertani broths) and blood agar plates [82].
Sample enrichment is another essential factor increasing
MALDI-TOF MS performance [23]. For the ID of a significant
proportion of yeasts and filamentous fungi, an extraction
method prior to the analysis in the mass spectrometer is
recommended to obtain appropriate spectra. Due to the low
marginal costs and the extreme speed, MALDI-TOF MS can
indeed improve laboratory efficiency when used early in ID
protocols. However, lengthier, more labour-intensive, and
costlier techniques can be reserved for the minority of
isolates not detected with high confidence by MALDI-TOF
MS.
MALDI-TOF MS also has the potential to identify
pathogens in direct samples, such as urine and blood
cultures. Furthermore, the potential for ID at the serotype
or strain level, and antibiotic resistance profiling within
minutes make MALDI-TOF MS an ongoing revolution in the
clinical microbiology laboratory. However, despite replacing
phenotypic IDs of bacteria, there is still no consensus
standard regarding requirements for MALDI-TOF MS va-
lidation prior to clinical use in the United States [83]. Indeed,
density of organism spotting onto a steel target, direct over-
lay of bacteria with CHCA, and microbiological variables,
such as culture medium, growth temperature, serial sub-
cultures, and modification of ID acceptance criteria at
species level, may be considered critical issues for technical
validation. Application of optimized BioTyper score cutoffs
for species-level IDs, increased ID rate by 6.75% for the
enteric Gram-negative bacteria and 4.25% for the non-
fermenting Gram-negative bacteria, compared to the
manufacturer's recommended score cutoff [83]. Indeed,
MALDI-TOF MS, using the unamended database supplied
with the system BioTyper, still suffers in identifying bac-
teria commonly isolated in cystic fibrosis (CF) patients, such
as mucoid Pseudomonas aeruginosa, when direct colony
technique and routinely extraction procedure are performed,
compared to phenotyping methods (e.g., culture, API systems)
[81]. However, in the paper by Desai et al. [72] a set of
29 Burkholderia cepacia complex isolates, were identified by
MALDI-TOF MS for 85% of the isolates, compared to only 34%
with the conventional methods. Another study [84] recently
focused on pre-analytical steps to identify Gram-positive cocci,
considering three sample preparation methods: the “direct
transfer”, the “direct transfer-FA method” and the “ethanol-FA
extraction”. The rate of correct IDs at genus level was
approximately 99% for all three sample preparation methods.
The species ID rate was significantly higher for the “direct
transfer-FA method” and the “ethanol-FA extraction” (both
77.6%), compared to the “direct transfer” (64.1%). In a following
prospective study, 1619 clinical isolates of Gram-positive cocci
were analysed under routine conditions, using the “direct
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methods. For 95.6% of the isolates a correspondence between
conventional and MALDI-TOF MS ID was observed. Two major
limitations were encountered using MALDI-TOF MS: the
differentiation of Streptococcus mitis group members and the
Streptococcus dysgalactiae ID. However, the Bruker MALDI
BioTyper, using the “direct transfer-FA” sample preparation
method, appeared highly reliable for Gram-positive cocci ID,
suggesting an alternative algorithm in clinical laboratory
[84]. Another paper [85] has recently considered the ID of 239
aerobic Gram-positive isolates, evaluating four direct smear
methods, including heavy (H) and light smears (L), with and
without a direct FA overlay and assigning as “quality
measure” a numerical value. The authors found that H + FA
produced optimal MALDI-TOF MS ID scores and the highest
percentage of correctly identified bacteria. Using a score of
≥2.0, 183/239 isolates (76.6%) were identified at genus-level
and out of the 181 isolates resolved at species-level, 141
(77.9%) were correctly identified. To maximize the number of
correct IDs, minimizing mis-IDs, the data were analysed
using a score of ≥1.7 for genus- and species-level ID. Using
this score, 220/239 isolates (92.1%) were identified at
genus-level and of the 181 isolates resolved to species,
167 (92.2%) presented accurate species ID. A subset of0
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considered. Frequent subcultures increased the number of
unidentified isolates, while incubation temperature and
media subcultures did not alter ID rate [84]. Microorganism
IDs directly from positive blood culture represent a major
step forward to reduce the ID turnaround time (TAT) and
may lead to earlier appropriate treatment of bacteremia.
Indeed, in the paper by Vlek et al. [86], authors demonstrated
the role of direct MALDI-TOF MS, routinely performed on
positive blood cultures. In total, 253 episodes of bacteremia
were included in the study, of which 89 approached by
MALDI-TOF MS-based diagnosis and 164 without MALDI-TOF
MS usage (e.g., control period). Remarkably, the direct
performance of MALDI-TOF MS on positive blood cultures
reduced the species ID time by 28.8 h and was associated
with an 11.3% increase in the number of patients receiving
appropriate antibiotic treatment 24 h after positivity (64.0%
without MALDI-TOF MS versus 75.3% with MALDI-TOF MS
usage) [84]. Also in the diagnosis of urinary tract infections
(UTIs), ID of the urinary tract pathogens (automated screening,
plate cultures, and biochemical characteristics-based IDs) may
be implemented by MALDI-TOF MS. With this purpose, in the
paper by Ferreira et al. [53], 260 urine samples, detected as
positive by the flow cytometry screeningdevice (UF-1000i), wereErtapenem
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positive in the screening device but negative in culture,
consistently with MALDI-TOF MS negativity. Two-hundred
and thirty-five samples displayed significant growth of a single
morphological type in culture, and 220 of them showed
bacterial growth of >105 CFU/ml. Microorganism IDs in this
group were almost coincident at the species level in 202 cases
(91.8%) and at the genus level in 204 cases (92.7%). The most
frequent microorganismwas E. coli (173 isolates). MALDI-TOF
MS identified this microorganism directly from the urine
sample in 163 cases (94.2%) [53]. These data showed that
MALDI-TOF MS allows bacterial ID directly from infected
urine in a short time, with great accuracy, and especially
when Gram-negative bacteria with high bacterial counts are
involved.3. MALDI-TOF MS-based microbial typing and
antibiotic resistance profiling
The robustness of the MALDI-TOF MS method is allowing
microbiologists to obtain extremely stable proteomic
profiles down to “strain” taxonomic level, despite high
microorganism variability. Therefore, the range of applications
of MALDI-TOF MS is constantly growing, from rapid species ID
to labour-intensive proteomics on bacterial physiology
(functional proteomics). So far, several studies have contributed
to describe antibiotic resistance investigation performed by
MALDI-TOF MS, with a thorough application into clinical
microbiology pipelines, as reported in the pivotal paper by
Hrabák et al. [87] (Fig. 5). The authors suggested that future
perspectives should persist in three main directions, including
detection of: i) antibiotic modifications by degrading enzymes;
ii) resistance mechanism determinants through proteomics of
MDR bacteria; and iii) modifications of target sites, such as
ribosomal methylation. New approaches to study influx and
efflux processes in bacterial cells should be based on
quantification of antibiotics, opening new avenues for both
experimental and clinical microbiology [87]. Recently, peptidic
fingerprinting has been applied to highlight clonal distribution of
MDR Klebsiella pneumoniae strains in both paediatric [77] and adult
[88] nosocomial settings. In the paper by Bernaschi et al. [77], the
proteomic-based typingwascompared toother “typing”methods
such as PFGE and automatic (repetitive-sequence-based-PCR)
rep-PCR (DiversiLab System) in order to establish strain
correlation indexes. Antibiotic susceptibility and phenotypic
tests were also correlated by Berrazeg et al. [88] on 535
K. pneumoniae strains isolated in Algerian and French hospitals.
The Main Spectra (MSP) dendrogram obtained from MALDI-TOF
MS revealed five distinct clusters, significantly associated with
respiratory infections/extended-spectrum beta-lactamase (ESBL)
phenotype (Algeria), and UTIs/wild-type phenotype (France). In
both papers MALDI-TOF MS was found to be a promising tool
to identify and type K. pneumoniae strains according to their
phenotypic properties and epidemiological distributions. Re-
markably, MALDI-TOF MS can be nowadays complemented
with functional proteomics assays to determine ESBL and
carbapenemaseactivity inMDRstrains of E. coliandK. pneumoniae
[89] (Fig. 5). In some cases, as well as for anaerobic bacteria,susceptibility testing of clinical isolates is not considered
recommended in routine clinical practice and the treatments
are empirically established. However, periodic monitoring of
susceptibility patterns of anaerobic bacteria is appropriate.
Fingerprinting analyses, obtained by MALDI-TOF MS and
automated rep-PCR, were reported in a recent paper [90] also
on carbapenem resistance profiles ofmetallo-beta-lactamase
(MBL) producing Bacteroides fragilis strains. A total of 830
clinical isolates of B. fragilis group were studied, with
B. fragilis being the most prevalent species (59.5%). The
susceptibility range of B. fragilis group isolates was
represented by: penicillin; amoxicillin/clavulanic; piperacillin-
tazobactam; cefoxitin; ertapenem; imipenem; clindamycin
and metronidazole. The percentage of sensitive isolates
did not change significantly over time for the entire set
of molecules, with a slight increase in the resistance rate
to ertapenem and imipenem. Six imipenem-resistant
isolates were MBL-producing and PCR positive for cfiA
(imipenem-cefoxitin-hydrolyzing enzyme) gene. Both MALDI-
TOF MS and automated rep-PCR, revealed a great genetic
diversity amongst carbapenem-producing strains, suggesting
the acquisition of novel resistance genes more than their
clonal dissemination. Indeed, both methods appeared to be
useful tools for fast and accurate ID and typing of B. fragilis
group in the daily laboratory routine at strain level.
Because of the relevant increase observed in Bacteroides
species isolated also from blood cultures and the
appearance of carbapenemase-producing strains [88],
antimicrobial susceptibility, at least in the most severe
patients, should be pursued in diagnostic pipelines.
Propionibacterium acnes is an anaerobic skin commensal of
relatively low pathogenicity. However, it is now emerging
as an important opportunistic pathogen in many clinical
situations, including late-stage prosthetic joint infections,
osteomyelitis, endocarditis, endophthalmitis, and post-
neurosurgical infections. At the population genetic level,
P. acnes can be differentiated into a number of distinct
phylogroups, known as types IA1, IA2, IB, IC, II and III,
which may be associated with different types of infections
and clinical conditions. The study by Nagy et al. [91]
evaluated MS-based typing for resolution of these genetic
groups after routine MALDI-TOF MS-based ID. A differen-
tiating library was created to type 48 P. acnes clinical
isolates and data were compared with multilocus sequence
typing (MLST) results. Most of the clinical isolates (19/48)
belonged to the type IA grouping, according to MALDI-TOF MS.
By MLST, all isolates were identified as type IA1. Twenty-one
clinical isolates belonged to the type IB cluster based on both
MALDI-TOF MS and MLST typing. Eight clinical isolates were
identified as type II strains by both typing methods and all the
type III reference strains could be distinguished by the presence
of a unique type III-specific peak (7238 Da) by the MALDI-TOF
MS, hence indicating MS as a reliable and powerful tool for
rapid ID/typing of P. acnes genetic groups [91]. Currently, early
detection of outbreaks of methicillin-resistant Staphylococcus
aureus (MRSA) and adequate infection controlmeasures are key
objectives in hospital hygiene. In order to reach them, the
potential of MALDI-TOF MS was compared to genetic typing
methods such as PFGE, spa typing (S. aureus A protein) or MLST
to describe epidemiologic relatedness of major clinical MRSA
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to the 5 major hospital-acquired MRSA clonal complexes
(CC5, CC8, CC22, CC30, CC45, as deduced from spa typing),
reproducible spectrum differences were observed at 13
characteristic m/z values, allowing robust discrimination
of the clonal complexes. Sixty independent clinical MRSA
isolates, tested for presence or absence of the 13
characteristic MALDI-TOF MS peaks, provided 15 different
profiles (MALDI types) and their hierarchical clustering
showed high concordance with the clonal complexes [92].
Remarkably, these proteomic “types”may have the potential to
become a valuable “first-line” tool for inexpensive and rapid
typing of MRSA in infection control. In the study by Sun et al.
[93], forty strains of S. aureus were investigated by both
MALDI-TOF MS and API Staph ID system, testing performance
of methicillin-resistance by Disk Diffusion Susceptibility
Testing, to set a rapid method for MRSA assessment.
Thirty-four strainswere identified byMALDI-TOFMSas S. aureus,
consistently with the API Staph ID system. Eleven strains were
identified as MRSA and 23 as methicillin-susceptible S. aureus
(MSSA). All 34 strains were therefore clustered into 2 groups by
MALDI-TOF MS. The results were consistent with Disk Diffusion
Susceptibility Testing, indicating MALDI-TOF MS as a rapid
technique for MRSA ID and discrimination [93]. Also Burkholderia
group is intrinsically resistant to many antibiotics and rapid ID
is therefore crucial. However, referenceMALDI-TOFMSdatabases
are not suitable for reliable ID, especially for sibling species
such as Burkholderia pseudomallei and Burkholderia mallei, and
generation of dedicated libraries are therefore mandatory. In the
paper by Karger et al. [44], a collection of ten B. pseudomallei
and 17 B. mallei strains was used to generate a reference spectra
library. Samples of both species were identified by MALDI-TOF
MS, with a dedicated reference spectra library, but spectra
demonstrated a higher homogeneity in B. mallei than in
B. pseudomallei isolates. As expected for all closely related species,
the ID/typing process with MALDI BioTyper software required a
critical selection of spectra from reference strains [44]. When a
dedicated reference set is used and spectra of high quality are
acquired, very-closely related species can be unambiguously
distinguished. Amongst bacteria causing foodborne illness,
Yersinia enterocolitica is a Gram-negative coccobacillus-shaped
bacterium, usually genotyped by exploiting the ail (attachment
and invasion locus) gene target, used as target for the detection of
pathogenic Y. enterocolitica strains in food testing. The ail PCR
does not detect, however, strains of biotype 1A (BT1A), which
are considered as non-pathogenic because lacking both virulence
plasmid and chromosomally encoded virulence genes. How-
ever, in some recent reports, BT1A strains were described as
harbouring the ail gene [63]. Whole-cell MALDI-TOFMS approach
wasapplied toY. enterocoliticaandclearly classified the ail-positive
biotype 1A strain within the cluster of BT1A strains, support-
ing PFGE-based strain patterns and genotyping analyses (ystB,
ystA, virF and yadA virulence genes) of both pathogenic and
non-pathogenic Y. enterocolitica strains and allowing a more
comprehensive assessment of Yersinia strains pathogenicity
[63]. Often, genetic and phenotypic heterogenicity require
multiple-gene target combined typing methods (e.g., seven
house keeping genes, atpD, gapA, guaA, mutM, nuoD, ppsA
and recA). Amongst the others, the Stenotrophomonas genus
is highly variable and, of the nine recognized species,only Stenotrophomonas maltophilia is of clinical importance
relevance. Based on DNA-sequences, the genus encompasses
“genogroups” of DNA-similarity below 97%, predominantly
comprising strains of environmental origin. Therefore, to
unveil the uneven distribution of environmental isolates
within genogroups and reveal the genetic relationships
within the genus, an easy and reliable approach is needed
for Stenotrophomonas spp. ID. In the study byVasileuskaya-Schulz
et al. [94] a multi-locus sequence analysis (MLSA) was applied
for the analysis of 21 S. maltophilia of environmental origin,
Stenotrophomonas spp. and related genera. The genotypic out-
comes were compared with MALDI-TOF MS typing. The MLSA
provided reliable inter- and intra-species discrimination of all
tested isolates that correlated with the MALDI-TOF MS data and
provided the indication that some S. maltophilia genogroups of
predominantly environmental origin are still to be classified [92].
MALDI-TOF MS typing seems to unravel also carbapenem
resistance in Acinetobacter spp., appearing as a promising option
to identify resistance patterns in routine use. In the paper
by Alvarez-Buylla et al. [95], significant peaks for imipenem
detection were identified, establishing optimal bacterial
inoculums and test incubation time with and without
dipicolinic acid and Zn2+, in order to distinguish between
MBL and oxacillinases. Indeed, Acinetobacter genus contains
17 reference strains of Acinetobacter species and 7 geno-
mospecies (i.e., species 10 and 11), whose variability was
analysed by MALDI-TOF MS, indicating that Acinetobacter
bereziniae and Acinetobacter guillouiae represent two phenetically
and phylogenetically distinct groups within the Acinetobacter
genus. Despite their overall phenotypic similarity, the ability
to oxidize D-glucose and grow at 38 °C was employed in
the differentiation of these two species. Interestingly, the
strains of A. bereziniae originated mainly from human clinical
specimens, whereas A. guillouiae strains were isolated from
different environmental sources in addition to human speci-
mens [96].
In the study by Böhme et al. [97], 70 reference strains from
culture collections, including important seafood-borne path-
ogenic and spoilage bacterial species, and 50 strains isolated
from commercial seafood, were analysed by both 16S rRNA
sequencing and MALDI-TOF MS fingerprinting. The first
analysis only identified the 50% of the strains at species
level, appearing particularly poor at identifying Pseudomonas
spp. and Bacillus spp. Conversely, MALDI-TOF MS identified
76% of the strains at species level. The MS spectral data
were submitted to the SpectraBank database (http://www.
spectrabank.org), performing peak mass cluster analysis by
the web application SPECLUST andmaking the data available
to the scientific community. Groupings appeared consistent
with 16S rRNA-based phylogenetic results. Interestingly, for
theMALDI-TOFMS analysis a higher discriminating potential
was observed, especially for Pseudomonas and Bacillus genera,
thus demonstrating to be an efficacious typing tool to extend
phenotypic and genotypic approaches [97]. Nontypable
H. influenzae (NTHi) and Haemophilus haemolyticus exhibit
different pathogenicities; however, a reliable strategy for
differentiating these strains is still lacking. In the study by
Zhu et al. [30] MALDI-TOF MS was tested as a potential
differentiating method combined to 16S rRNA and re-
combinase A (recA) gene analyses. The ORD was supported
Table 1 –Main studies on MALDI-TOF MS-based assays compared to reference molecular methods.
Intention of
the study
Microorganism No.
samples
Reference methods Results References
MALDI-TOF MS
typing
Klebsiella pneumoniae
multi-drug resistant
(MDR) strains
7 Pulsed-field gel electrophoresis
(PFGE) and automated
repetitive-sequence-based PCR
(rep-PCR) genotyping
MALDI-TOF MS typing was
concordant with reference
methods
[77]
MALDI-TOF MS
typing and
antibiotic
susceptibility
tests
K. pneumoniae
strains
535 Multi-locus sequence analysis
(MLSA)
MALDI-TOF MS typing revealed
five distinct clusters, associated
with type of infections, country
strain origin and antibiotic
susceptibility
[88]
MALDI-TOF
MS-based
antibiotic
susceptibility
tests
Escherichia coli and K.
pneumoniae
9 Vitek-2, Phoenix automated
systems and manual disk method
for extended-spectrum
β-lactamase (ESBL) phenotype;
Hodge test and
kpc gene PCR for carbapenemase
susceptibility
Antibiotic susceptibility test
MALDI-TOF MS-based determined ESBL
and carbapenemase activity
in concordance with reference
methods
[89]
MALDI-TOF MS
typing
Bacteroides fragilis 830 rep-PCR Both MALDI-TOF MS and rep-PCR
methods revealed a great genetic
diversity amongst
carbapenem-producing strains
[90]
MALDI-TOF MS
typing
Propionibacterium
acnes
48 Multilocus sequence typing (MLST) MALDI-TOF MS typing was
concordant with reference method
[91]
Epidemiological
survey based
on
MALDI-TOF MS
typing
Methicillin-resistant
Staphylococcus aureus
(MRSA)
85 PFGE, S. aureus A protein (spa
typing) and MLST
MALDI-TOF MS-based hierarchical
clustering showed high
concordance with the clonal complexes
[92]
Rapid method
for MRSA
assessment
based on
MALDI-TOF MS
typing
S. aureus 40 API Staph ID system and disk
diffusion susceptibility testing
(DDST)
MALDI-TOF MS-based results
were consistent with DDST,
indicating MALDI-TOF MS as a
rapid technique for MRSA ID and
discrimination
[93]
MALDI-TOF MS
reference
spectra library
for
Burkholderia spp.
Burkholderia
pseudomallei,
Burkholderia mallei
27 – A careful selection of spectra
from reference strains was required.
When a dedicated reference set is
used and spectra of high quality are
acquired, it is possible to distinguish
both species unambiguously
[44]
MALDI-TOF MS
typing for the
assessment of
Yersinia strains
pathogenicity
Yersinia enterocolitica – ail gene PCR, PFGE, genotyping
analyses of virulence genes
MALDI-TOF MS approach classified
the ail-positive biotype 1A strain
within the cluster of BT1A strains
[63]
MALDI-TOF MS
typing
Stenotrophomonas
spp.
21 MLSA MALDI-TOF MS typing was
concordant with the reference
method for the inter- and
intra-species discrimination
[94]
MALDI-TOF MS
typing and
antibiotic
susceptibility
tests
Acinetobacter spp. 24 – Optimal bacterial inoculum and
incubation time with and without
dipicolinic acid and Zn2+ were
established in order to distinguish
between metallo-β-lactamase and
oxacillinases producing strains.
[95]
MALDI-TOF MS
typing
Acinetobacter
bereziniae sp. nov.
Acinetobacter
guillouiae sp. nov.
33 Amplified fragment length
polymorphism (AFLP), amplified
rDNA restriction, tDNA intergenic
length polymorphism analyses,
rpoB and 16S rRNA sequencing
A. bereziniae and A. guillouiae
represented two phenetically and
phylogenetically distinct groups
within the genus Acinetobacter
[96]
MALDI-TOF MS
typing
Seafood-borne
pathogenic and
spoilage bacterial
species
120 16S rRNA sequencing MALDI-TOF MS typing showed a
higher discriminating power of
the 16S rRNA sequencing for both
Pseudomonas and Bacillus genera
[97]
(continued on next page)
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Table 1 (continued)
Intention of
the study
Microorganism No.
samples
Reference methods Results References
MALDI-TOF MS
typing
Nontypable
Haemophilus
influenzae (NTHi)
and Haemophilus
haemolyticus
72 16S rRNA sequencing and
recombinase A (recA) gene analysis
MALDI-TOF MS typing showed the
advantage of integrating high
throughput, accuracy, speed and
consistency with epidemiological data
[30]
MALDI-TOF MS
identification
and typing in
paediatric
samples
Clinical yeasts 303 Vitek-2 and 25-28S rDNA
sequencing
MALDI-TOF MS based methods showed
higher performance,
accuracy, speed and consistency with
epidemiological data with respect to the
reference methods
[24]
MALDI-TOF MS
typing in
neonatal
intensive
care units
Candida parapsilosis 19 PCR of simple sequence repeats
(SSRs)
MALDI-TOF MS typing was
concordant with the reference
method
[98]
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MS evaluation. The searching on ORD provided 76.9% of the
NTHi (40/52) and none of the H. haemolyticus strains correctly
identified at the species level. However, all NTHi and
H. haemolyticus strains were accurately recognized at the
species level by scanning NRD. Interestingly, geographic-
dependent clustering was observed and, hence, Chinese and
foreign H. influenzae strains were categorized into two distinct
groups,withH. influenzae andH. haemolyticus also separated into
two distinct categories. Compared to the existing methods,
indeed, MALDI-TOF MS seems to have the advantage of
integrating high throughput, accuracy, speed and con-
sistency with epidemiological data [30] (Table 1).4. MALDI-TOF MS-based ID and typing
of yeasts
Recent studies on Candida spp. outbreaks have shown an
increased incidence of bloodstream infections especially in
neonatal intensive care units caused by Candida parapsilosis
species, highlighting the need for their appropriate ID and
epidemiological tracking. Several systems are available for
molecular epidemiological and taxonomic studies of fungal
infections: i) PFGE, still represents the gold standard for many
microorganisms typing, including yeasts; ii) simple sequence
repeats (SSRs) and iii) rep PCR, both based on repeated genome
regions. Recently, MALDI-TOF MS has been widely used to
identify and type microorganisms involved in nosocomial
outbreaks. Indeed, robustness and reproducibility of MALDI-
TOF MS profiles have been thoroughly described with reference
to Candida species, body site, and antimycotic treatment [24]. In
the study by Pulcrano et al. [98], 19 strains of C. parapsilosis,
isolated from blood cultures of neonates, were genotyped by
eight SSR markers and by MALDI-TOF MS. DNA- and MS-based
results were compared in terms of discriminatory power
to identify similarities amongst the isolates and study
evolutionary changes in the C. parapsilosis population. The
research showed that MS was a useful ID technique, also
effective in monitoring the strain spread which is a keypoint for nosocomial infections control [98]. The Cryptococcus
neoformans/Cryptococcus gattii species complex, a yeast-like
fungus, comprises two sibling species, divided into eight
major molecular types, C. neoformans VNI-VNIV and C. gattii
VGI-VGIV. These genotypes differ in host range, epide-
miology, virulence, antifungal susceptibility and geographic
distribution. The current phenotypic and molecular IDs for
species/molecular types often rely on real-time PCR-based
methods, usually time consuming and expensive [99]. Recently,
MALDI-TOF MS has been considered as an alternative for the
rapid ID of C. neoformans and C. gattii at intra- and inter-species
level. In a recent paper [100], 164 C. neoformans/C. gattii isolates,
including four inter-species hybrids, were studied by MALDI-
TOF MS and spectra correctly identified 100% of the isolates,
grouped according to the currently recognized species,
C. neoformans, C. gattii, and potential hybrids, and consistently
with their major molecular types. Greater spectral differ-
ences were observed for C. neoformans than for C. gattii
molecular types, most likely reflecting a closer phylogenetic
relationship amongst the latter group. However, spectra were
obtained not from intact yeast cells, but from FA-extracted
cells, whose spectra were matched against an extended
validated NRD, containing spectra of all eight major
molecular types. Even in this case, MALDI-TOF MS can be
considered a rapid ID tool for a correct recognition of the two
currently recognized human pathogenic Cryptococcus species,
characterized by high biological and taxonomic complexity
[100] (Table 1).5. Mono and polymicrobial communities: the
case of blood cultures
It is nowadays clear that MALDI-TOF MS fingerprinting has
become a powerful tool in microbiological diagnostics.
MALDI-TOF MS also has the potential to directly identify
pathogens in urine samples and blood cultures and, because
of lengthier, more labour-intensive, and costlier techniques
reserved for isolate ID in such samples, there is a drive
to apply MALDI-TOF MS directly to samples from positive
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[23]. Indeed, this technology is expected to improve, as major
challenge, especially the clinical management and guidance
for chemotherapy. Sepsis is a life-threatening disease with
high rates of morbidity and mortality worldwide; especially
onco-haematological paediatric patients and newborns, par-
ticularly preterm infants, are at high risk of severe infections
and sepsis due to their deficient and/or immature immunologic
defences. Rapid ID of fungi or bacteria commonly causing sepsis
could allowprompt species-specific therapy, leading to improved
clinical outcomesand reductionofmortality, decreaseof cost and
length of hospitalization and lower development of antimicrobial
resistance [101]. Blood culture is still considered thegold standard
for the diagnosis of sepsis, allowing both ID and susceptibility
testing. However, it suffers from several limitations, including
lack of rapidity, requiring 1–3 days to become positive and
additional 1–2 days for microorganisms ID and susceptibility
testing. New diagnostic tests, that could rapidly and accurately
identify bacterial and fungi species, are therefore required,
including improvement of databases and softwares [102,103].
Several attempts have been made to identify bacteria from
positive blood cultures, especially using molecular biology and
real-time-based PCRs. Rapid methods using microarrays,
hybridization probes, and even flow cytometry techniques have
been recently reviewed for diagnosis of bloodstream infections
[104].
5.1. The pre-analytical step: the usage of
homebrew methods
Several studies [105] have evaluated the contribution of
MALDI-TOFMS formicroorganism ID in positive blood cultures.
The crucial pre-analytical step consists in separating the
bacteria from cellular components in absence of which no ID
is obtained. However, whatever is the protocol used, it seems
that different centrifugation steps are needed, followed by lysis
of blood elements to obtain reliable IDs. Nevertheless, different
various drawbacks may be encountered such as correct ID
of viridans Streptococci and Streptococcus pneumoniae and
detection of the only predominant species in polymicrobial
blood cultures [105]. These limitations highlight the importance
of Gram staining to verify the presence of one or more micro-
organism morphology or stain, before performing MALDI-TOF
MS. Ferroni et al. [106] reported a significant progress in sample
preparation. Once the blood culture was identified as positive, a
mild detergent was employed to lyse the cellular membranes
within a few minutes, hence allowing bacterial ID in less than
30 min and candidating MALDI-TOF MS as the fastest of all
techniques for bacterial ID directly from blood culture broths. In
order to speed up the ID process, La Scola and Raoult [103],
evaluated the bacterial ID directly from positive blood cultures.
They prospectively analysed routine MALDI-TOF MS bacterial
ID in blood cultures by two different protocols involving
successive centrifugations and then lysis by TFA or FA. Out of
the 562 blood culture broths detected asmonomicrobic positive,
370 (66%) were correctly identified. Changing the protocol from
TFA- to FA-based, Staphylococci ID was improved, and
complete correct ID increased from 59 to 76%. Lack of ID was
observed mostly for viridans Streptococci. Amongst 22 positive
polymicrobic blood culture broths, only one of the species wasidentified in 18 samples, no species were identified in two
samples and false species IDs were obtained in two cases.
Indeed, it seems that MALDI-TOF MS is an efficient method for
direct routine IDs of bacterial isolates in blood cultures, with the
exception of polymicrobial samples and viridans Streptococci
[103].
5.2. The pre-analytical step: the usage of the
Sepsityper™ kit
The performance of the MALDI Sepsityper™ kit for bacteria ID
was evaluated by Kok et al. [107], applying manufacturer's
specified bacterial ID criteria (spectral scores ≥1.700–1.999 and
≥2.000 ID to genus and species level, respectively) and comparing
results to standard phenotypicmethods. Five hundred and seven
positive blood cultures were examined, of which 379 (74.8%; 358
monomicrobial and 21 polymicrobial) were identified by
MALDI-TOF MS; particularly, 132/195 Gram-positive (67.7%) and
149/163 Gram-negative (91.4%) from monomicrobial blood
cultures were correctly identified at genus and species level,
respectively. Spectral scores <1.700 (no ID) were obtained in 128/
507 (25.2%) positive blood cultures, including 31.6% and 32.3% of
Gram-positive and polymicrobial blood cultures, respectively.
Significantly, more Gram-negative organisms were identi-
fied compared to Gram-positive organisms at species level
(p < 0.0001). Five blood cultures were misidentified, but only at
species level, including four monomicrobial blood cultures with
Streptococcus oralis/mitis that were misidentified as S. pneumoniae.
Therefore, a diagnostic algorithm for positive blood culture
broths, including Gram staining and MALDI-TOF MS should
identify the majority of pathogens, particularly at genus level
[107]. In another study [108], Sepsityper™kitwas evaluated versus
conventional separator gel columns: theMALDI-TOFMS-based ID
of Gram-negative bacteria was significantly enhanced using the
Sepsityper™ kit (99 versus 68% correct ID). For Gram-positive
bacteria, 73%were correctly identified byMALDI-TOFMSwith the
Sepsityper™ kit andonly 59%with the separator gel tube assay. A
major problemof bothmethodswas the poor ID of Gram-positive
grape-like clustered cocci. As differentiation of S. aureus from
coagulase-negative Staphylococci is of clinical importance, a PCR
was additionally established, capable of identifying S. aureus
directly from positive blood cultures, thus filling this diagnostic
gap, with the additional value to detect MRSA in Staphylococci
and vancomycin resistance in Enterococci [108]. Another study
[109] compared Sepsityper™ kit to conventional method for
bacterial preparation in order to performsusceptibility testing: no
significant differences were observed in Gram-negative bacilli ID,
regardless of the bacterial separation method used. However, ID
was higher for Gram-positive cocci when the Sepsityper™
method was compared to an in-house method (ID 100% versus
84.15% for Staphylococci and ID 85.71% versus 57.14% for
Enterococci, both at genus level). Therefore, the study suggested
that Sepsityper™method resultedmore adequate for the further
ID of Gram-positive cocci by MALDI-TOF MS [109]. Another
protocol for bacterial ID from blood culture broths in hospital
routine was assayed by Moussaoui et al. [110]. Before processing
for bacterial protein extraction, 503 samples, examined over a
three month period, were treated by Vacutainer gel separator
tubes. Including polymicrobial samples, 193 of 213 of Gram-
negative bacteria (91.08%) and 284 of 319 of Gram-positive
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Enterobacteriaceae constituted 35.15% of all species found,
Staphylococcaceae 37.96%, Streptococcaceae and Enterococcaceae
20.85%, Pseudomonadaceae 1.69% and anaerobes 2.44%. In most of
the polymicrobial samples, only one species present was
identified (80.9%). Seven isolates remained misidentified as
S. pneumoniae, all belonging to S. mitis. S. aureus were better
identified when grown on anaero-aerobic medium, and MALDI
BioTyper ID scores as low as 1.4 were consistent in four
successive outcomes for the same species. This protocol
correlated with conventional microbiology procedures by up to
90%, and by >95% for only monomicrobial samples, definitely
decreasing TAT for bacteria ID in blood cultures [110].
The study by Del Chierico et al. [111] evaluated the usage
of MALDI-TOF MS on blood cultures (Microflex LT mass
spectrometer, Bruker Daltonics), comparing MS-based IDs to
conventional method Vitek 2 outcomes. With this aim, 200
blood cultures positive to BACTEC System (BD diagnostics)
were Gram stained and cultured on solid media for microbe
ID and antibiotic susceptibility by Vitek 2 (Biomerieux) or
Phoenix (BD diagnostics). For MALDI-TOF MS ID, six ml from
each bottle was centrifuged in gel Vacutainer tubes toFig. 6 – MALDI-TOF MS-based workflow for positive blood cultu
protocols (e.g., gel Vacutainer). The conventional methods based o
with the two fast MALDI-TOFMS-basedworkflows. In the inset, thseparate microorganisms. The peptides were extracted by
the standard ethanol/FA protocol and analysed by Microflex
mass spectrometer (Bruker Daltonics). Generated spectra
were processed by BioTyper software with scores associated
with the correct ID probability. Results were compared to
the reference biochemical systems and, when discordant,
verified by MALDI-TOF MS on isolated colonies. Amongst the
200 analysed samples, 173 were monomicrobial cultures, of
which 109 correctly identified by both methods, 19 discordant
and 45 identified only by traditional techniques. Interestingly,
the scores were reliable at species level for 57/109 samples, at
genera level for 29/109, while a not reliable ID was obtained for
23/109. Fourteen blood cultures had polymicrobial growth and
MALDI-TOFMSprovided a correct ID for only onemicrobe in 11/
14. Twenty-one out of the 200 isolates were identified as yeasts
by Vitek-2, but only 3 were detected by MALDI-TOF MS.
Particularly, 13 false positive samples on BACTEC system had
no MALDI-TOF MS ID (Fig. 6). Therefore, also in this
experimental setting, MALDI-TOF MS appeared a useful
method to support routine ID of bacterial isolates from
blood culture, because of its rapidity (around 45 min) and
high sensitivity and specificity (65% and 72%, respectively).res designed by including both Sepsityper™ and homebrew
n Gram staining and biochemical identification are compared
e tableswith ID results for each identified species are reported.
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algorithm is not representative of the true ID; ii) failure
of yeast ID; iii) in polymicrobial samples microbe dis-
crimination is not achieved; iv) the sensitivity is affected
by the spot loading capacity (Fig. 6) [111]. Additionally, a
comparison between gel Vacutainer and MALDI Sepsityper
™-based extraction methods performed on further 50
positive blood cultures, revealed 38/50 and 45/50 correct
IDs, respectively, with a sensitivity increment of 18.4%
obtained by using the MALDI Sepsityper™ kit (Fig. 6) [111].
New methodological approaches also developed sample
enrichment into specific growing media before extraction
process and prior to MS analysis [112].
In the recent study by Chen et al. [113], the performance of
two commercial MALDI-TOF MS systems, VITEK MS IVD
(bioMerieux) and Microflex LT BioTyper (Bruker Daltonics), was
evaluated on direct bacterial ID on positive blood cultures with
the use of the commercial MALDI Sepsityper™ extraction
method. Amongst the 181 monomicrobial cultures analysed,
both systems generated genus to species level IDs amongst
>90% of specimens (BioTyper: 177/181, 97.8%; VITEK MS IVD:
167/181, 92.3%). Generally, the BioTyper system generated
significantly more accurate IDs than the VITEK MS IVD system
for the monomicrobial cultures and was able to identify the
minority species amongst polymicrobial blood cultures. An
in-house extraction method was also evaluated versus the
Sepsityper™ kit on both MALDI-TOF MS systems. The in-house
method could generatemore correct IDs at genus level than the
Sepsityper™ kit (96.7 versus 93.5%) on the BioTyper system,
whereas they exhibited the same performance (88.0%) on the
VITEKMS IVD system. The study by Chen et al. [113] confirmed
the practical advantages of MALDI-TOF MS and their “in-house”
extraction method, which reduced the reagent cost to US $1/
sample and the TAT to 3 h, highly effective indexes for a
diagnostic microbiology service [112].5.3. The post-analytical step: the ID processing algorithm
Post-analytical modifications of ID cut-off scores may also
improve diagnostic accuracy. In the paper by Nonnemann et
al. [114], a cut-off score of 1.5 was considered and compared
to the recommended 1.8. The 3-month study on positive
blood cultures was carried out to evaluate whether the
Sepsityper™ Kit with BioTyper 2.0 software could be used as
a fast diagnostic tool for bacteria and fungi and whether a
1.5 cut-off score could improve species IDs, compared with
the recommended score of 1.8. Two hundred and fifty-six
positive blood cultures from 210 patients and 19 blood
cultures spiked with fungi were examined. Using the cut-off
score of 1.8, 81% Gram-negative bacteria were identified at
species level compared to 84% using a cut-off score of 1.5.
For Gram-positive bacteria, 44% were identified at species
level with a cut-off of 1.8, compared to 55% with the 1.5
value. The entire ID rate was 63% (cut-off 1.5) and 54%
(cut-off 1.8); 77% of fungal species were identified with both
log scores. The recent study confirmed the MALDI-TOF MS
as a reliable fast diagnosis tool for Gram-negative bacteria
and fungi but lesser for Gram-positives. However, the 1.5
cut-off score increased the diagnosis for both Gram-positiveand -negative bacteria [114]. Lastly, results obtained so far
by MALDI-TOF MS applied to direct bacterial ID on positive
blood cultures have been encouraging but have also shown
some limitations, mainly related to bacterial growth and the
presence of interfering substances belonging to blood
cultures. Even if it is highly efficient now, after a decade
of experiments, the technique is currently still being
improved. However, it lacks standardization and exhaustive
databases andmore efficient softwares are necessary. Thus,
it is likely that bacterial IDs from complex matrices, such as
blood cultures and urines, will become more and more
accurate in the near future.6. Proteomics and metaproteomics
of microbial ecosystems
The proteomic analysis of complex microbial communities is
a new promising research field aiming at assessing the
“bioreactor” features of a microbial community. Description
of gut microbiota phylotypes needs employment of original
“metaproteomic” pipelines, implemented by appropriate
non-redundant repository databases for interrogation and
operational taxon units (OTUs) inference. However, axenic
culture-based MALDI-TOF MS IDs may still act as reference
and corroborating outcome for metaproteomics-obtained
OTUs (Del Chierico et al., 2013, JPROT-D-13-00094, Accepted).
Indeed, the term “metaproteomics” was coined only in
2004 by Wilmes and Bond [115] for large-scale ID of the
whole protein content of an environmental community of
prokaryotic microorganisms. In this pivotal study, successful
extraction and purification of the entire proteome enabled
its large-scale characterization by 2D-PAGE, quadrupole TOF
MS and de novo peptide sequencing analysis. Afterwards,
Ram et al. [116] conducted a very comprehensivemetaproteomic
study combining “shotgun” MS-based proteomics analysis
with gene expression techniques to evaluate in situmicrobial
activity of a low complexity natural microbial biofilm. In
this experimental work, they characterized more than 2000
proteins, of which 215 were novel, from the most abundant
microorganisms. A rich literature has provided a lot of infor-
mation into low complexity microbial communities [117–119],
human saliva [120], human urine [121], marine [122], environ-
mental [123] and human faecal samples [124–128].
Although it is still an early approach, metaproteomics
may have the potential to provide extensive new functional
information for diverse ecosystems and especially for the
principal microbe–host ecosystem which is the human
gut. In this regard, metaproteomics has functionally
characterized the microbiota in the developing human
infant GI tract [124], and discovered temporal stability of a
core proteome for an established intestinal microbiome of an
adult human [128]. Verberkmoes et al. [125], realized a high
level of metaproteome characterization, focusing on the
unaltered adult human gut microbiomes for two healthy
subjects, highlighting the strong integrated relationship
between microbial and human proteins [125]. Finally, Erickson
et al. [126], integrating metaproteomics and metagenomics,
characterized the human host-microbiota signatures of human
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investigations include irregular species distribution, dynamic
range of protein expression levels within microorganisms, and
large genetic variety within the microbial communities [129].
In spite of these difficulties, metaproteomics has the great
potential to link the genetic multiplicity and activities of
microbial communities with their impact on the ecosystem
function, but needs to deal with the cornerstone culturomics
[130,131] and the metagenomics based on “next generation
sequencing” (NGS) evidence.7. Outlook on other MALDI-TOF
MS applications and future developments
Traditionalmicrobial typing technologies for the characterization
of pathogenic microorganisms and monitoring of their global
spread are often difficult to standardize and poorly portable; they
also lack sufficient ease of use, throughput and automation. To
overcome these problems, the use of comparative sequencing by
MALDI-TOF MS for automated high-throughput microbial DNA
sequence analysis has been included into pathogen ID and
characterization pipelines and has been implemented. For
example, data derived from the public MLST database
(http://pubmlst.org/neisseria) were utilized in the study by
Honish et al. [132] to establish a reference set of expected
peak patterns. A model pathogen, Neisseria meningitidis, was
used to validate the technology and explore its applicability as
an alternative to dideoxy sequencing (DS). One hundred
N. meningitidis samples were typed by comparing MALDI-TOF
MS fingerprints of the standard MLST loci to reference
sequences available in the public MLST database. IDs were
obtained in two working days. Results were in concordance
with classical DSwith 98% correct automatic ID. Sequence types
(STs) of 89 samples were represented in the database, seven
samples revealed new STs, including three new alleles, and
four samples contained mixed populations of multiple STs.
The approach showed interlaboratory reproducibility and
allowed for the exchange of MS fingerprints to study
the geographic spread of epidemic N. meningitidis strains.
The Sequenom MassARRAY iPLEX single-nucleotide poly-
morphism (SNP) typing platform MALDI-TOF MS, coupled
with single-base extension PCR for high-throughput
multiplex SNP detection, was investigated for S. aureus
MRSA genotyping, by developing a 16-plex MassARRAY
iPLEX GOLD assay (MRSA-iPLEX) [133]. The method was
evaluated with 147 MRSA isolates, and the results were
compared with those of an established SYBR Green-based
real-time PCR system utilizing the same SNP-binary
markers. A total of 2352 markers belonging to 44 SNP-
binary profiles were analysed by both real-time PCR and
MRSA-iPLEX. With real-time PCR as the reference standard,
MRSA-iPLEX correctly assigned 2298 of the 2352 (97.7%)
markers. MRSA-iPLEX provided optimal throughput for
MRSA genotyping and was, on a reagent basis, more
cost-effective than the real-time PCR methods. Therefore, the
16-plex MRSA-iPLEX represented a suitable alternative to SYBR
Green-based real-time PCR typing of major sequence types and
clonal complexes of MRSA. In the study by Bouakaze et al. [134],the potential use of another SNP genotyping Sequenom was
investigated for the simultaneous analysis of 16 SNPs, previously
validated as a useful tool for Mycobacterium tuberculosis complex
(MTBC) species ID and for the classification of MTBC isolates
into distinct genetic lineages (principal genetic groups and
SNP cluster groups). In this context, the authors developed a
16-plex iPLEX assay based on an allele-specific-primer
single-base-extension reaction using the iPLEX Gold kit
(Sequenom), followed by MALDI-TOF MS analysis on the
commercially Sequenom MassARRAY platform. This assay
was tested on a panel of 55 well-characterized MTBC strains
that were also genotyped for the same loci using the
previously reported SNaPshot assay, as well as 10 non-
MTBC Mycobacteria and 4 bacteria not belonging to the
Mycobacterium genus. All MTBC samples were successfully
analysed with the iPLEX assay, which yielded clear allelic
data for 99.9% of the SNPs (879 out of 880). No false-positive
results were obtained with the negative controls. Compared
to the SNaPshot assay, the newly developed 16-plex iPLEX
assay produced fully concordant results that allowed reliable
differentiation of MTBC species and recognition of lineages,
thus demonstrating its potential value in diagnostic, epidemio-
logical, and evolutionary applications. Compared to the SNaP-
shot approach, the implementation of the iPLEX technology
could offer a higher throughput and could be a more flexible
and cost-effective option for microbiology laboratories. In
another study [135], a new multiplexed primer extension-
based spoligotyping assay using MALDI-TOF MS improved the
classical reverse line blot hybridization assay (RLHA) with
respect to reproducibility, throughput, process flow, ease of
use, and data analysis. Validation of the MALDI-TOF MS-based
spoligotyping assay with two sample sets (i.e., totally 326
samples), resulted in 96.6% concordance (315/326), when the full
spoligotype patterns were compared with the results of standard
spoligotyping, and 99.9% concordance, when the results were
compared with those of individual primer extension assays. Ten
strains showed discordant results with one or two spacer
differences from the membrane-based spoligotyping results.
Most discordant samples were identified to be the outcome of
ambiguities in the interpretation of weak hybridization signals in
the RLHA and sequence variations in the spacer regions. The
authors established a new automated primer extension assay
and successfully validated it for the use on the routine typing of
MTBC strains in the research and public health laboratory
environments, possibly extendable to antibiotic resistance
markers [135].
During the past five years, MALDI-TOF MS has become a
powerful tool for routine IDs inmany clinical laboratories. Seng
et al. [136] analysed 11-year experience in routine ID of clinical
isolates (40 months using MALDI-TOF MS and 91 months using
conventional phenotypic identification, CPI). Amongst the
286,842 clonal isolates, 284,899 isolates of 459 species were
well-identified. The remaining 1951 isolates were misidentified
and required confirmation using a second phenotypic ID for 670
isolates and a molecular technique for 1273 isolates of 339
species. MALDI-TOF MS annually identified 112 species, i.e., 36
species/10,000 isolates, compared to 44 species, i.e., 19 species/
10,000 isolates, for CPI. Only 50 isolates required second
phenotypic IDs during the MALDI-TOF MS period (i.e., 4.5
re-IDs/10,000 isolates) compared with 620 isolates during the
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species rarely described as human pathogens were reported,
including 48 phenotypic techniques (22 using CPI and 37
MALDI-TOF MS). Another 75 rare species were identified using
molecular methods. Therefore, MALDI-TOF MS reduced the
time required for ID by 55-fold and 169-fold, and the cost by
5-fold and 96-fold, compared with CPI and gene sequencing,
respectively.
Recently, whole-cell MALDI-TOF MS has also allowed the
ID of mammalian cells such as macrophages. The whole-cell
MALDI-TOF spectra of macrophages stimulated with IFN-γ
and IL-4, produced spectra with peaks ranging from 2 to
12 kDa, very different from those of unstimulated and
stimulated macrophages. Interestingly, the fingerprints in-
duced by M1 agonists (i.e., IFN-γ, TNF, LPS and LPS + IFN-γ) and
M2 agonists (i.e., IL-4, TGF-β1 and IL-10) were specific and
readily identifiable. Thus,whole-cellMALDI-TOFMSwas able to
characterise M1 and M2 macrophage subtypes, but also
fingerprints induced by extracellular or intracellular bacteria
were bacterium-specific. This approach is opening a new
avenue to study immune response in the clinical setting, by
monitoring the various activation patterns of immune cells
in pathological conditions [137].
The ability to rapidly identify bacterial species, rarely
described as pathogens in specific clinical specimens, will help
us to study the clinical burden resulting from the emergence of
these species as human pathogens, definitely suggesting
MALDI-TOF MS an alternative to molecular methods in clinical
laboratories [136]. Further implementations in sample pro-
cessing, enrichment and interpretative ID score algorithms
still need to be accomplished,makingMALDI-TOFMS the future
shared automated platform in clinical microbiology and the
robust and reference reservoir for NGS data generation and
interpretation.Acknowledgments
This work was supported by the Ministry of Health, Ricerca
Corrente (RC201302P002991) and Grant 201103X002675 (“The
proteomics in microbiology: from single pathogens to systems
biology”), Bambino Gesù Children's Hospital, IRCCS, to LP. We
like to thank Andreina Santoro for the careful revision of
the English language.R E F E R E N C E S
[1] Lederberg J. The dawning of molecular genetics. Trends
Microbiol 2000;8:194–5.
[2] Waldbauer JR, Rodrigue S, Coleman ML, Chisholm SW.
Transcriptome and proteome dynamics of a light–dark
synchronized bacterial cell cycle. PLoS One 2012;7(8):e43432.
[3] Rogers AB. Gastric Helicobacter spp. in animal models:
pathogenesis and modulation by extragastric coinfections.
Methods Mol Biol 2012;921:175–88.
[4] Di Palma S, Hennrich ML, Heck AJ, Mohammed S. Recent
advances in peptide separation by multidimensional liquid
chromatography for proteome analysis. J Proteomics
2012;75(13):3791–813.[5] Tipton JD, Tran JC, Catherman AD, Ahlf DR, Durbin KR,
Kelleher NL. Analysis of intact protein isoforms by mass
spectrometry. J Biol Chem 2011;286:25451–8.
[6] Messana I, Cabras T, Iavarone F, Vincenzoni F, Urbani A,
Castagnola M. Unraveling the different proteomic platforms.
J Sep Sci 2013;36(1):128–39.
[7] Wu Q, Yuan H, Zhang L, Zhang Y. Recent advances on
multidimensional liquid chromatography-mass
spectrometry for proteomics: from qualitative to quantitative
analysis—a review. Anal Chim Acta 2012;731:1–10.
[8] Cui W, Rohrs HW, Gross ML. Top-down mass spectrometry:
recent developments, applications and perspectives.
Analyst 2011;136(19):3854–64.
[9] Wu CC, MacCoss MJ. Shotgun proteomics: tools for the
analysis of complex biological systems. Curr Opin Mol Ther
2002;4(3):242–50.
[10] Bogdanov B, Smith RD. Proteomics by FTICR mass
spectrometry: top down and bottom up. Mass Spectrom Rev
2005;24(2):168–200.
[11] Michalski A, Damoc E, Lange O, Denisov E, Nolting D, Müller
M, et al. Ultra high resolution linear ion trap Orbitrap mass
spectrometer (Orbitrap Elite) facilitates top down LC MS/MS
and versatile peptide fragmentation modes. Mol Cell
Proteomics 2012;11(3) [O111.013698].
[12] Di Girolamo F, Del Chierico F, Caenaro G, Lante I, Muraca M,
Putignani L. Human serum proteome analysis: new source
of markers in metabolic disorders. Biomark Med
2012;6(6):759–73.
[13] Intelicato-Young J, Fox A. Mass spectrometry and tandem
mass spectrometry characterization of protein patterns,
protein markers and whole proteomes for pathogenic
bacteria. J Microbiol Methods 2013;92(3):381–6.
[14] Del Chierico F, Vernocchi P, Bonizzi L, Carsetti R, Castellazzi
AM, Dallapiccola B, et al. Early-life gut microbiota under
physiological and pathological conditions: the central role of
combined meta-omics-based approaches. J Proteomics
2012;75(15):4580–7.
[15] Kliem M, Sauer S. The essence on mass spectrometry based
microbial diagnostics. Curr Opin Microbiol
2012;15(3):397–402.
[16] Köser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown
NM, Farrington M, et al. Routine use of microbial whole
genome sequencing in diagnostic and public health
microbiology. PLoS Pathog 2012;8(8):e1002824.
[17] Hsieh SY, Tseng CL, Lee YS, Kuo AJ, Sun CF, Lin YH, et al.
Highly efficient classification and identification of human
pathogenic bacteria by MALDI-TOF MS. Mol Cell Proteomics
2008;7(2):448–56.
[18] Del Chierico F, Masotti A, Onori M, Fiscarelli E, Mancinelli L,
Ricciotti G, et al. MALDI-TOF MS proteomic phenotyping of
filamentous and other fungi from clinical origin. J
Proteomics 2012;75(11):3314–30.
[19] Seibold E, Maier T, Kostrzewa M, Zeman E, Splettstoesser W.
Identification of Francisella tularensis by whole-cell matrix-
assisted laser desorption ionization-time of flight mass
spectrometry: fast, reliable, robust, and cost-effective
differentiation on species and subspecies levels. J Clin
Microbiol 2010;48(4):1061–9.
[20] Parisi D, Magliulo M, Nanni P, Casale M, Forina M, Roda A.
Analysis and classification of bacteria by matrix-assisted
laser desorption/ionization time-of-flight mass
spectrometry and a chemometric approach. Anal Bioanal
Chem 2008;391(6):2127–34.
[21] Bizzini A, Greub G. Matrix-assisted laser desorption
ionization time-of-flight mass spectrometry, a revolution in
clinical microbial identification. Clin Microbiol Infect
2010;16(11):1614–9.
[22] Cherkaoui A, Hibbs J, Emonet S, Tangomo M, Girard M,
Francois P, et al. Comparison of two matrix-assisted laser
84 J O U R N A L O F P R O T E O M I C S 9 7 ( 2 0 1 4 ) 6 9 – 8 7desorption ionization-time of flight mass spectrometry
methods with conventional phenotypic identification for
routine identification of bacteria to the species level. Clin
Microbiol 2010;48(4):1169–75.
[23] Steensels D, Verhaegen J, Lagrou K. Matrix-assisted laser
desorption ionization-time of flight mass spectrometry for
the identification of bacteria and yeasts in a clinical
microbiological laboratory: a review. Acta Clin Belg
2011;66(4):267–73.
[24] Putignani L, Del Chierico F, Onori M, Mancinelli L, Argentieri
M, Bernaschi P, et al. MALDI-TOF mass spectrometry
proteomic phenotyping of clinically relevant fungi. Mol
Biosyst 2011;7(3):620–9.
[25] Croxatto A, Prod'hom G, Greub G. Applications of MALDI-TOF
mass spectrometry in clinical diagnostic microbiology. FEMS
Microbiol Rev 2012;36(2):380–407.
[26] Biswas S, Rolain JM. Use of MALDI-TOF mass spectrometry
for identification of bacteria that are difficult to culture. J
Microbiol Methods 2013;92(1):14–24.
[27] Moliner C, Ginevra C, Jarraud S, Flaudrops C, Bedotto M,
Couderc C, et al. Rapid identification of Legionella species by
mass spectrometry. J Med Microbiol 2010;59(Pt 3):273–84.
[28] Fujinami Y, Kikkawa HS, Kurosaki Y, Sakurada K, Yoshino M,
Yasuda J. Rapid discrimination of Legionella bymatrix-assisted
laser desorption ionization time-of-flight mass spectrometry.
Microbiol Res 2011;166(2):77–86.
[29] Svarrer CW, Uldum SA. The occurrence of Legionella species
other than Legionella pneumophila in clinical and
environmental samples in Denmark identified by mip gene
sequencing and matrix-assisted laser desorption ionization
time-of-flight mass spectrometry. Clin Microbiol Infect
2012;18(10):1004–9.
[30] Zhu B, Xiao D, Zhang H, Zhang Y, Gao Y, Xu L, et al. MALDI-TOF
MS distinctly differentiates nontypable Haemophilus influenzae
from Haemophilus haemolyticus. PLoS One 2013;8(2):e56139.
[31] Ilina EN, Borovskaya AD, Serebryakova MV, Chelysheva VV,
Momynaliev KT, Maier T, et al. Application of matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry for the study of Helicobacter pylori. Rapid
Commun Mass Spectrom 2010;24(3):328–34.
[32] Fournier PE, Couderc C, Buffet S, Flaudrops C, Raoult D.
Rapid and cost-effective identification of Bartonella species
using mass spectrometry. J Med Microbiol 2009;58(Pt
9):1154–9.
[33] Pignone M, Greth KM, Cooper J, Emerson D, Tang J.
Identification of mycobacteria by matrix-assisted laser
desorption ionization-time-of-flight mass spectrometry. J
Clin Microbiol 2006;44(6):1963–70.
[34] Wang J, Chen WF, Li QX. Rapid identification and
classification of Mycobacterium spp. using whole-cell protein
barcodes with matrix assisted laser desorption ionization
time of flight mass spectrometry in comparison with
multigene phylogenetic analysis. Anal Chim Acta
2012;716:133–7.
[35] Shitikov E, Ilina E, Chernousova L, Borovskaya A, Rukin I,
Afanas'ev M, et al. Mass spectrometry based methods for
the discrimination and typing of mycobacteria. Infect Genet
Evol 2012;12(4):838–45.
[36] Hettick JM, Kashon ML, Slaven JE, Ma Y, Simpson JP, Siegel
PD, et al. Discrimination of intact mycobacteria at the strain
level: a combined MALDI-TOF MS and biostatistical analysis.
Proteomics 2006;6(24):6416–25.
[37] La Scola B, Fournier PE, Raoult D. Burden of emerging
anaerobes in the MALDI-TOF and 16S rRNA gene sequencing
era. Anaerobe 2011;17(3):106–12.
[38] Fournier R, Wallet F, Grandbastien B, Dubreuil L, Courcol R,
Neut C, et al. Chemical extraction versus direct smear for
MALDI-TOF mass spectrometry identification of anaerobic
bacteria. Anaerobe 2012;18(3):294–7.[39] Veloo AC, Knoester M, Degener JE, Kuijper EJ. Comparison of
two matrix-assisted laser desorption ionisation-time of
flight mass spectrometry methods for the identification of
clinically relevant anaerobic bacteria. Clin Microbiol Infect
2011;17(10):1501–6.
[40] Nagy E, Maier T, Urban E, Terhes G, Kostrzewa M, ESCMID
Study Group on Antimicrobial Resistance in Anaerobic
Bacteria. Species identification of clinical isolates of
Bacteroides by matrix-assisted laser-desorption/ionization
time-of-flight mass spectrometry. Clin Microbiol Infect
2009;15(8):796–802.
[41] Culebras E, Rodríguez-Avial I, Betriu C, Gómez M, Picazo JJ.
Rapid identification of clinical isolates of Bacteroides
species by matrix-assisted laser-desorption/ionization
time-of-flight mass spectrometry. Anaerobe
2012;18(1):163–5.
[42] Mellmann A, Cloud J, Maier T, Keckevoet U, Ramminger I,
Iwen P, et al. Evaluation of matrix-assisted laser desorption
ionization-time-of-flight mass spectrometry in
comparison to 16S rRNA gene sequencing for species
identification of nonfermenting bacteria. J Clin Microbiol
2008;46(6):1946–54.
[43] Jacquier H, Carbonnelle E, Corvec S, Illiaquer M, Le Monnier
A, Bille E, et al. Revisited distribution of nonfermenting
Gram-negative bacilli clinical isolates. Eur J Clin Microbiol
Infect Dis 2011;30(12):1579–86.
[44] Karger A, Stock R, Ziller M, Elschner MC, Bettin B, Melzer F,
et al. Rapid identification of Burkholderia mallei and
Burkholderia pseudomallei by intact cell matrix-assisted laser
desorption/ionisation mass spectrometric typing. BMC
Microbiol 2012;12:229.
[45] Friedrichs C, Rodloff AC, Chhatwal GS, Schellenberger W,
Eschrich K. Rapid identification of Viridans streptococci by
mass spectrometric discrimination. J Clin Microbiol
2007;45(8):2392–7.
[46] Dupont C, Sivadon-Tardy V, Bille E, Dauphin B, Beretti JL,
Alvarez AS, et al. Identification of clinical
coagulase-negative staphylococci, isolated in
microbiology laboratories, by matrix-assisted laser
desorption/ionization-time of flight mass spectrometry
and two automated systems. Clin Microbiol Infect
2010;16(7):998–1004.
[47] McEllistrem MC. Genetic diversity of the pneumococcal
capsule: implications for molecular-based serotyping.
Future Microbiol 2009;4(7):857–65.
[48] Dunne EM, Ong EK, Moser RJ, Siba PM, Phuanukoonnon S,
Greenhill AR, et al. Multilocus sequence typing of
Streptococcus pneumoniae by use of mass spectrometry. J Clin
Microbiol 2011;49(11):3756–60.
[49] Ikryannikova LN, Lapin KN, Malakhova MV, Filimonova AV,
Ilina EN, Dubovickaya VA, et al. Misidentification of
alpha-hemolytic streptococci by routine tests in clinical
practice. Infect Genet Evol 2011;11(7):1709–15.
[50] Loonen AJ, Jansz AR, Bergland JN, Valkenburg M, Wolffs PF,
van den Brule AJ. Comparative study using phenotypic,
genotypic, and proteomics methods for identification of
coagulase-negative staphylococci. J Clin Microbiol
2012;50(4):1437–9.
[51] Moon HW, Lee SH, Chung HS, Lee M, Lee K. Performance of
the Vitek MS matrix-assisted laser desorption ionization
time-of-flight mass spectrometry system for identification of
Gram-positive cocci routinely isolated in clinical microbiology
laboratories. J Med Microbiol 2013;62(Pt 9):1301–6.
[52] Ng LS, Sim JH, Eng LC, Menon S, Tan TY. Comparison of
phenotypic methods and matrix-assisted laser desorption
ionisation time-of-flight mass spectrometry for the
identification of aero-tolerant Actinomyces spp. isolated from
soft-tissue infections. Eur J Clin Microbiol Infect Dis
2012;31(8):1749–52.
85J O U R N A L O F P R O T E O M I C S 9 7 ( 2 0 1 4 ) 6 9 – 8 7[53] Ferreira L, Sánchez-Juanes F, González-Avila M,
Cembrero-Fuciños D, Herrero-Hernández A,
González-Buitrago JM, et al. Direct identification of urinary
tract pathogens from urine samples bymatrix-assisted laser
desorption ionization-time of flight mass spectrometry. J
Clin Microbiol 2010;48(6):2110–5.
[54] Lista F, Reubsaet FA, De Santis R, Parchen RR, de Jong AL,
Kieboom J, et al. Reliable identification at the species level of
Brucella isolates with MALDI-TOF-MS. BMC Microbiol
2011;11:267.
[55] Nyvang Hartmeyer G, Kvistholm Jensen A, Böcher S,
Damkjaer Bartels M, Pedersen M, Engell Clausen M, et al.
Mass spectrometry: pneumococcal meningitis verified and
Brucella species identified in less than half an hour. Scand J
Infect Dis 2010;42(9):716–8.
[56] Everley RA, Mott TM, Wyatt SA, Toney DM, Croley TR. Liquid
chromatography/mass spectrometry characterization of
Escherichia coli and Shigella species. J Am Soc Mass Spectrom
2008;19(11):1621–8.
[57] Zacharczuk K, Sulikowska A, Nowacka E, Szych J,
Gierczyński R. Rapid identification of Yersinia enterocolitica by
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS). Med Dosw Mikrobiol
2012;64(2):123–8.
[58] Karger A, Ziller M, Bettin B, Mintel B, Schares S, Geue L.
Determination of serotypes of Shiga toxin-producing
Escherichia coli isolates by intact cell matrix-assisted laser
desorption ionization-time of flight mass spectrometry.
Appl Environ Microbiol 2011;77(3):896–905.
[59] Tani A, Sahin N, Matsuyama Y, Enomoto T, Nishimura N,
Yokota A, et al. High-throughput identification and
screening of novelMethylobacterium species using whole-cell
MALDI-TOF/MS analysis. PLoS One 2012;7(7):e40784.
[60] Uhlik O, Strejcek M, Junkova P, Sanda M, Hroudova M, Vlcek C,
et al. Matrix-assisted laser desorption ionization (MALDI)-time
of flight mass spectrometry- and MALDI biotyper-based
identification of cultured biphenyl-metabolizing bacteria from
contaminated horseradish rhizosphere soil. Appl Environ
Microbiol 2011;77(19):6858–66.
[61] Böhme K, Fernández-No IC, Barros-Velázquez J, Gallardo JM,
Cañas B, Calo-Mata P. Rapid species identification of seafood
spoilage and pathogenic Gram-positive bacteria by MALDI-TOF
mass fingerprinting. Electrophoresis 2011;32(21):2951–65.
[62] Kiehntopf M, Melcher F, Hänel I, Eladawy H, Tomaso H.
Differentiation of Campylobacter species by surface-enhanced
laser desorption/ionization-time-of-flight mass
spectrometry. Foodborne Pathog Dis 2011;8(8):875–85.
[63] Kraushaar B, Dieckmann R, Wittwer M, Knabner D,
Konietzny A, Mäde D, et al. Characterization of a Yersinia
enterocolitica biotype 1A strain harbouring an ail gene. J Appl
Microbiol 2011;111(4):997–1005.
[64] Lindenstrauss AG, Pavlovic M, Bringmann A, Behr J,
Ehrmann MA, Vogel RF. Comparison of genotypic and
phenotypic cluster analyses of virulence determinants and
possible role of CRISPR elements towards their incidence in
Enterococcus faecalis and Enterococcus faecium. Syst Appl
Microbiol 2011;34(8):553–60.
[65] Stephan R, Cernela N, Ziegler D, Pflüger V, Tonolla M, Ravasi
D, et al. Rapid species specific identification and subtyping
of Yersinia enterocolitica by MALDI-TOF mass spectrometry. J
Microbiol Methods 2011;87(2):150–3.
[66] Fernández-No IC, Böhme K, Calo-Mata P, Cañas B, Gallardo
JM, Barros-Velázquez J. Isolation and characterization of
Streptococcus parauberis from vacuum-packaging
refrigerated seafood products. Food Microbiol
2012;30(1):91–7.
[67] Böhme K, Morandi S, Cremonesi P, Fernández No IC,
Barros-Velázquez J, Castiglioni B, et al. Characterization
of Staphylococcus aureus strains isolated from Italiandairy products by MALDI-TOF mass fingerprinting.
Electrophoresis 2012;33(15):2355–64.
[68] Seibold E, Bogumil R, Vorderwülbecke S, Al Dahouk S,
Buckendahl A, Tomaso H, et al. Optimized application of
surface-enhanced laser desorption/ionization time-of-flight
MS to differentiate Francisella tularensis at the level of
subspecies and individual strains. FEMS Immunol Med
Microbiol 2007;49(3):364–73.
[69] Murray PR. Matrix-assisted laser desorption ionization
time-of-flightmass spectrometry: usefulness for taxonomy
and epidemiology. Clin Microbiol Infect
2010;16(11):1626–30.
[70] Vanlaere E, Sergeant K, Dawyndt P, Kallow W, Erhard M,
Sutton H, et al. Matrix-assisted laser desorption
ionisation-time-of-flight mass spectrometry of intact
cells allows rapid identification of Burkholderia cepacia
complex. J Microbiol Methods 2008;75(2):279–86.
[71] Mott T, Soler M, Grigsby S, Medley R, Whitlock GC.
Identification of potential diagnostic markers among
Burkholderia cenocepacia and B. multivorans supernatants. J
Clin Microbiol 2010;48(11):4186–92.
[72] Desai AP, Stanley T, Atuan M, McKey J, Lipuma JJ, Rogers B,
et al. Use of matrix assisted laser desorption ionisation-time
of flight mass spectrometry in a paediatric clinical laboratory
for identification of bacteria commonly isolated from cystic
fibrosis patients. J Clin Pathol 2012;65(9):835–8.
[73] Fernández-Olmos A, García-Castillo M, Morosini MI,
Lamas A, Máiz L, Cantón R. MALDI-TOF MS improves
routine identification of non-fermenting Gram negative
isolates from cystic fibrosis patients. J Cyst Fibros
2012;11(1):59–62.
[74] Schaumann R, Knoop N, Genzel GH, Losensky K, Rosenkranz
C, Stîngu CS, et al. A step towards the discrimination of beta-
lactamase-producing clinical isolates of Enterobacteriaceae and
Pseudomonas aeruginosa by MALDI-TOF mass spectrometry.
Med Sci Monit 2012;18(9):MT71–7.
[75] Ferreira L, Vega Castaño S, Sánchez-Juanes F,
González-Cabrero S, Menegotto F, Orduña-Domingo A, et al.
Identification of Brucella by MALDI-TOF mass spectrometry.
Fast and reliable identification from agar plates and blood
cultures. PLoS One 2010;5(12):e14235.
[76] Carbonnelle E, Nassif X. Applications of MALDI–TOF–MS in
clinical microbiology laboratory. Med Sci (Paris)
2011;27(10):882–8.
[77] Bernaschi P, Del Chierico F, Petrucca A, Argentieri A,
Ciofi Degli Atti M, Ciliento G. Microbial tracking of
multidrug-resistant Klebsiella pneumoniae isolates in a
pediatric hospital setting. Int J Immunopathol
Pharmacol 2013;26(2):463–72.
[78] Böhme K, Fernández-No IC, Barros-Velázquez J, Gallardo
JM, Cañas B, Calo-Mata P. SpectraBank: an open access
tool for rapid microbial identification by MALDI-TOF MS
fingerprinting. Electrophoresis 2012;33(14):2138–42.
[79] Mungall CJ, Gkoutos GV, Smith CL, Haendel MA, Lewis SE,
AshburnerM. Integrating phenotype ontologies acrossmultiple
species. Genome Biol 2010;11(1):R2 [http://genomebiology.com/
2010/11/1/R2].
[80] Lau AF, Drake SK, Calhoun LB, Henderson CM, Zelazny AM.
Development of a clinically comprehensive database and a
simple procedure for identification of molds from solid
media by matrix-assisted laser desorption ionization-time
of flight mass spectrometry. J Clin Microbiol
2013;51(3):828–34.
[81] Valentine N, Wunschel S, Wunschel D, Petersen C, Wahl K.
Effect of culture conditions on microorganism identification
by matrix-assisted laser desorption ionization mass
spectrometry. Appl Environ Microbiol 2005;71(1):58–64.
[82] Jarman KH, Cebula ST, Saenz AJ, Petersen CE, Valentine NB,
Kingsley MT, et al. An algorithm for automated bacterial
86 J O U R N A L O F P R O T E O M I C S 9 7 ( 2 0 1 4 ) 6 9 – 8 7identification using matrix-assisted laser
desorption/ionization mass spectrometry. Anal Chem
2000;72(6):1217–23.
[83] Ford BA, Burnham CA. Optimization of routine
identification of clinically relevant Gram-negative bacteria
using MALDI-TOF MS and the Bruker Biotyper. J Clin
Microbiol 2013;51(5):1412–20.
[84] Schulthess B, Brodner K, Bloemberg GV, Zbinden R,
Böttger EC, Hombach M. Identification of Gram-positive
cocci using MALDI-TOF MS: comparison of different
preparation methods and implementation of a practical
algorithm for routine diagnostics. J Clin Microbiol
2013;51(6):1834–40.
[85] Tekippe EM, Shuey S, Winkler DW, Butler MA, Burnham CA.
Optimizing identification of clinically relevant Gram-positive
organisms using the Bruker Biotyper MALDI-TOF MS system. J
Clin Microbiol 2013;51(5):1421–7.
[86] Vlek AL, Bonten MJ, Boel CH. Direct matrix-assisted laser
desorption ionization time-of-flight mass spectrometry
improves appropriateness of antibiotic treatment of
bacteremia. PLoS One 2012;7(3):e32589.
[87] Hrabák J, Chudácková E, Walková R. Matrix-assisted laser
desorption ionization-time of flight (MALDI-TOF) mass
spectrometry for detection of antibiotic resistance
mechanisms: from research to routine diagnosis. Clin
Microbiol Rev 2013;26(1):103–14.
[88] Berrazeg M, Diene SM, Drissi M, Kempf M, Richet H,
Landraud L, et al. Biotyping of multidrug-resistant Klebsiella
pneumoniae clinical isolates from France and Algeria using
MALDI-TOF MS. PLoS One 2013;8(4):e61428.
[89] Sparbier K, Schubert S, Weller U, Boogen C, Kostrzewa M.
Matrix-assisted laser desorption ionization-time of flight
mass spectrometry-based functional assay for rapid
detection of resistance against β-lactam antibiotics. J Clin
Microbiol 2012;50(3):927–37.
[90] Treviño M, Areses P, Peñalver MD, Cortizo S, Pardo F, del
Molino ML, et al. Susceptibility trends of Bacteroides fragilis
group and characterisation of carbapenemase-producing
strains by automated REP-PCR and MALDI TOF. Anaerobe
2012;18(1):37–43.
[91] Nagy E, Urbán E, Becker S, Kostrzewa M, Vörös A,
Hunyadkürti J, et al. MALDI-TOF MS fingerprinting
facilitates rapid discrimination of phylotypes I, II and III of
Propionibacterium acnes. Anaerobe 2013;20:20–6.
[92] Wolters M, Rohde H, Maier T, Belmar-Campos C, Franke G,
Scherpe S, et al. MALDI-TOF MS fingerprinting allows for
discrimination of major methicillin-resistant
Staphylococcus aureus lineages. Int J Med Microbiol
2011;301(1):64–8.
[93] Sun Z, Zhang W, Chen X. Rapid method study of
methicillin-resistant Staphylococcus aureus identified by
matrix-assisted laser desorption ionization-time of flight
mass spectrometry. J Hyg Res 2011;40(3):375–8.
[94] Vasileuskaya-Schulz Z, Kaiser S, Maier T, Kostrzewa M, Jonas
D. Delineation of Stenotrophomonas spp. by multi-locus
sequence analysis and MALDI-TOF mass spectrometry. Syst
Appl Microbiol 2011;34(1):35–9.
[95] Alvarez-Buylla A, Picazo JJ, Culebras E. Optimized method
for Acinetobacter spp carbapenemase detection and
identification by MALDI-TOF MS. J Clin Microbiol
2013;51(5):1589–92.
[96] Nemec A, Musílek M, Sedo O, De Baere T, Maixnerová M, van
der Reijden TJ, et al. Acinetobacter bereziniae sp. nov. and
Acinetobacter guillouiae sp. nov., to accommodate Acinetobacter
genomic species 10 and 11, respectively. Int J Syst Evol
Microbiol 2010;60(Pt 4):896–903.
[97] Böhme K, Fernández-No IC, Pazos M, Gallardo JM,
Barros-Velázquez J, Cañas B, et al. Identification and
classification of seafood-borne pathogenic and spoilagebacteria: 16S rRNA sequencing versus MALDI-TOF MS
fingerprinting. Electrophoresis 2013;34(6):877–87.
[98] Pulcrano G, Roscetto E, Iula VD, Panellis D, Rossano F,
Catania MR. MALDI-TOF mass spectrometry and
microsatellite markers to evaluate Candida parapsilosis
transmission in neonatal intensive care units. Eur J Clin
Microbiol Infect Dis 2012;31(11):2919–28.
[99] Putignani L, D'Arezzo S, Paglia MG, Visca P. DNA-based
detection of human pathogenic fungi: dermatophytes,
opportunists, and causative agents of deep mycoses. In:
Gherbawy Y, Voigt K, editors. Molecular Identification of
Fungi. Berlin Heidelberg: Springer-Verlag; 2010. p. 357–415.
[100] Firacative C, Trilles L, Meyer W. MALDI-TOF MS enables the
rapid identification of the major molecular types within the
Cryptococcus neoformans/C. gattii species complex. PLoS One
2012;7(5):e37566.
[101] Lucignano B, Ranno S, Liesenfeld O, Pizzorno B, Putignani L,
Bernaschi P, et al. Multiplex PCR allows rapid and accurate
diagnosis of bloodstream infections in newborns and
children with suspected sepsis. J Clin Microbiol
2011;49(6):2252–8.
[102] Emonet S, Shah HN, Cherkaoui A, Schrenzel J. Application
and use of various mass spectrometry methods in clinical
microbiology. Clin Microbiol Infect 2010;16(11):1604–13.
[103] La Scola B, Raoult D. Direct identification of bacteria in
positive blood culture bottles by matrix-assisted laser
desorption ionisation time-of-flight mass spectrometry.
PLoS One 2009;4(11):e8041.
[104] Klouche M, Schröder U. Rapid methods for diagnosis of
bloodstream infections. Clin Chem Lab Med
2008;46(7):888–908.
[105] Drancourt M. Detection of microorganisms in blood
specimens using matrix-assisted laser desorption
ionization time-of-flight mass spectrometry: a review. Clin
Microbiol Infect 2010;16(11):1620–5.
[106] Ferroni A, Suarez S, Beretti JL, Dauphin B, Bille E, Meyer J,
et al. Real-time identification of bacteria and Candida
species in positive blood culture broths by matrix-assisted
laser desorption ionization-time of flight mass
spectrometry. J Clin Microbiol 2010;48(5):1542–8.
[107] Kok J, Thomas LC, Olma T, Chen SC, Iredell JR. Identification
of bacteria in blood culture broths using matrix-assisted
laser desorption-ionization Sepsityper™ and time of flight
mass spectrometry. PLoS One 2011;6(8):e23285.
[108] Klein S, Zimmermann S, Köhler C, Mischnik A, Alle W, Bode
KA. Integration of matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry in
blood culture diagnostics: a fast and effective approach. J
Med Microbiol 2012;61(Pt 3):323–31.
[109] Juiz PM, Almela M, Melción C, Campo I, Esteban C, Pitart C,
et al. A comparative study of two different methods of
sample preparation for positive blood cultures for the rapid
identification of bacteria using MALDI-TOF MS. Eur J Clin
Microbiol Infect Dis 2012;31(7):1353–8.
[110] Moussaoui W, Jaulhac B, Hoffmann AM, Ludes B, Kostrzewa
M, Riegel P, et al. Matrix-assisted laser desorption ionization
time-of-flight mass spectrometry identifies 90% of bacteria
directly from blood culture vials. Clin Microbiol Infect
2010;16(11):1631–8.
[111] Del Chierico F, Ranno S, Lucignano B, D'Urbano M, Tredici S,
Bernaschi P, et al. Rapid identification of bacteria and fungi
from positive blood cultures by MALDI-TOF proteome
profiling, vol. 17, Issue Supplement s4. , P1841, 21th ECCMID,
7-10 May, Milan, Italy, 2011, CMI; 2011. p. S108–668 [May].
[112] Kroumova V, Gobbato E, Basso E, Mucedola L, Giani T,
Fortina G. Direct identification of bacteria in blood culture by
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry: a new methodological approach. Rapid
Commun Mass Spectrom 2011;25(15):2247–9.
87J O U R N A L O F P R O T E O M I C S 9 7 ( 2 0 1 4 ) 6 9 – 8 7[113] Chen JH, Ho PL, Kwan GS, She KK, Siu GK, Cheng VC, et al.
Direct bacterial identification in positive blood cultures by
use of two commercial matrix-assisted laser desorption
ionization-time of flight mass spectrometry systems. J Clin
Microbiol 2013 Jun;51(6):1733–9.
[114] Nonnemann B, Tvede M, Bjarnsholt T. Identification of
pathogenic microorganisms directly from positive blood
vials by matrix-assisted laser desorption/ionization time of
flight mass spectrometry. APMIS 2013;121(9):871–7.
[115] Wilmes P, Bond PL. The application of two-dimensional
polyacrylamide gel electrophoresis and downstream
analyses to a mixed community of prokaryotic
microorganisms. Environ Microbiol 2004;6(9):911–20.
[116] Ram RJ, Verberkmoes NC, Thelen MP, Tyson GW, Baker BJ,
Blake II RC, et al. Community proteomics of a natural
microbial biofilm. Science 2005;308(5730):1915–20.
[117] Lo I, Denef VJ, Verberkmoes NC, Shah MB, Goltsman D,
DiBartolo G, et al. Strain-resolved community proteomics
reveals recombining genomes of acidophilic bacteria.
Nature 2007;446(7135):537–41.
[118] Denef VJ, VerBerkmoes NC, Shah MB, Abraham P, Lefsrud M,
Hettich RL, et al. Proteomics-inferred genome typing (PIGT)
demonstrates inter-population recombination as a strategy
for environmental adaptation. Environ Microbiol
2009;11(2):313–25.
[119] Goltsman DS, Denef VJ, Singer SW, VerBerkmoes NC,
Lefsrud M, Mueller RS, et al. Community genomic and
proteomic analyses of chemoautotrophic iron-oxidizing
“Leptospirillum rubarum” (Group II) and “Leptospirillum
ferrodiazotrophum” (Group III) bacteria in acid mine drainage
biofilms. Appl Environ Microbiol 2009;75(13):4599–615.
[120] Rudney JD, Xie H, Rhodus NL, Ondrey FG, Griffin TJ. A
metaproteomic analysis of the human salivary microbiota
by three-dimensional peptide fractionation and tandem
mass spectrometry. Mol Oral Microbiol 2010;25(1):38–49.
[121] Fouts DE, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh
MJ, et al. Integrated next-generation sequencing of 16S rDNA
and metaproteomics differentiate the healthy urine
microbiome from asymptomatic bacteriuria in neuropathic
bladder associated with spinal cord injury. J Transl Med
2012;10:174.
[122] Kleiner M, Wentrup C, Lott C, Teeling H, Wetzel S, Young J,
et al. Metaproteomics of a gutless marine worm and its
symbiotic microbial community reveal unusual pathways
for carbon and energy use. Proc Natl Acad Sci U S A
2012;109(19):E1173–82.
[123] Schulze WX, Gleixner G, Kaiser K, Guggenberger G, Mann M,
Schulze ED. A proteomic fingerprint of dissolved organic
carbon and of soil particles. Oecologia 2005;142(3):335–43.
[124] Klaassens ES, de VosWM, Vaughan EE. Metaproteomics
approach to study the functionality of the microbiota in the
human infant gastrointestinal tract. Appl Environ Microbiol
2007;73(4):1388–92.
[125] Verberkmoes NC, Russell AL, Shah M, Godzik A, Rosenquist
M, Halfvarson J, et al. Shotgun metaproteomics of the
human distal gut microbiota. ISME J 2009;3(2):179–89.[126] Erickson AR, Cantarel BL, Lamendella R, Darzi Y,
Mongodin EF, Pan C, et al. Integrated
metagenomics/metaproteomics reveals human
host-microbiota signatures of Crohn's disease.
PLoS One 2012;7(11):e49138.
[127] Haange SB, Oberbach A, Schlichting N, Hugenholtz F, Smidt
H, von Bergen M, et al. Metaproteome analysis and
molecular genetics of rat intestinal microbiota reveals
section and localization resolved species distribution and
enzymatic functionalities. J Proteome Res
2012;11(11):5406–17.
[128] Kolmeder CA, de Been M, Nikkilä J, Ritamo I, Mättö J, Valmu
L, et al. Comparative metaproteomics and diversity analysis
of human intestinal microbiota testifies for its temporal
stability and expression of core functions. PLoS One
2012;7(1):e29913.
[129] Schneider T, Riedel K. Environmental proteomics: analysis
of structure and function of microbial communities.
Proteomics 2010;10(4):785–98.
[130] Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert
C, et al. Microbial culturomics: paradigm shift in the human
gut microbiome study. Clin Microbiol Infect
2012;18(12):1185–93.
[131] Lagier JC, Million M, Hugon P, Armougom F, Raoult D.
Human gut microbiota: repertoire and variations. Front Cell
Infect Microbiol 2012;2:136.
[132] Honisch C, Chen Y, Mortimer C, Arnold C, Schmidt O, van
den Boom D, et al. Automated comparative sequence
analysis by base-specific cleavage and mass spectrometry
for nucleic acid-based microbial typing. Proc Natl Acad Sci U
S A 2007;104(25):10649–54.
[133] Syrmis MW, Moser RJ, Whiley DM, Vaska V, Coombs GW,
Nissen MD, et al. Comparison of a multiplexed MassARRAY
system with real-time allele-specific PCR technology for
genotyping of methicillin-resistant Staphylococcus aureus.
Clin Microbiol Infect 2011;17(12):1804–10.
[134] Bouakaze C, Keyser C, Gonzalez A, Sougakoff W, Veziris N,
Dabernat H, et al. Matrix-assisted laser desorption
ionization-time of flight mass spectrometry-based single
nucleotide polymorphism genotyping assay using Iplex gold
technology for identification of Mycobacterium tuberculosis
complex species and lineages. J Clin Microbiol
2011;49(9):3292–9.
[135] Honisch C, Mosko M, Arnold C, Gharbia SE, Diel R, Niemann
S. Replacing reverse line blot hybridization spoligotyping of
the Mycobacterium tuberculosis complex. J Clin Microbiol
2010;48(5):1520–6.
[136] Seng P, Abat C, Rolain JM, Colson P, Lagier JC, Gouriet F, et al.
Identification of rare pathogenic bacteria in a clinical
microbiology laboratory: impact of matrix-assisted laser
desorption ionization-time of flight mass spectrometry.
J Clin Microbiol 2013;51(7):2182–94.
[137] Ouedraogo R, Daumas A, Ghigo E, Capo C, Mege JL, Textoris J.
Whole-cell MALDI-TOF MS: a new tool to assess the
multifaceted activation of macrophages. J Proteomics
2012;75(18):5523–32.
